Evgen Pharma PLC University of Manchester collaboration discovery (1273C)
February 06 2020 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 1273C
Evgen Pharma PLC
06 February 2020
Evgen Pharma plc
("Evgen Pharma" or the "Company")
University of Manchester collaboration discovery
Gene signature identified which may determine response to SFX-01
in ER+ breast cancer treatment
Evgen closer to predicting which patients are most likely to
benefit from breast cancer drug
Evgen Pharma plc (AIM: EVG), the clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, announces that its long-standing
collaboration with the University of Manchester has led to the
discovery of a gene signature that may predict patient response to
SFX-01 in advanced oestrogen receptor positive ("ER+") breast
cancer.
Evgen and the University of Manchester have previously shown
that SFX-01 inhibits activity of STAT3; a transcription factor
known to play a role in therapy resistance, and in the spread of
the cancer around the body. In this latest study, in hormone
therapy resistant patient tumours, SFX-01 was shown to inhibit
expression of key STAT3-regulated genes. This discovery yields
further insight into the mechanism of action of SFX-01 and moves
the Company closer to determining which patients are most likely to
respond favourably to treatment.
All the preclinical data accrued over the last eight years of
this research collaboration is to be published later this year and
the manuscript is now in open access and can be viewed at:
https://biorxiv.org/cgi/content/short/2020.02.03.932194v1
This follows a short preview of some of the data that was
presented by poster at last week's UK Interdisciplinary Breast
Cancer Symposium in Birmingham, UK.
Evgen Pharma has previously announced positive results from the
STEM trial of SFX-01 in metastatic breast cancer. Patients who
responded favourably to SFX-01 were able to access it post trial
and we can now report that one patient had their progressive
disease halted for a total of 597 days; an impressive duration in a
very difficult to treat and terminally ill patient population.
Steve Franklin, CEO of Evgen Pharma, said: "This latest data
from an eight-year collaboration with Manchester University, and
the forthcoming publication, are very positive developments for
both the design of future clinical trials and for supporting
business development activity with potential partners. The
University of Manchester have been tremendous collaborators and we
would like to thank them for their continued commitment and
enthusiasm.
"We continue to focus on our technical and commercial programmes
in-line with the Interim Statement, and remain confident of the
intrinsic value of SFX-01's therapeutic application in breast
cancer and other disease areas. We remain committed to building
shareholder value as we pursue our clinical programme in breast
cancer and potentially in other diseases via clinical trials
sponsored by academic and clinical centres of excellence."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Stephen Franklin, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane / Manasa Patil (ECM)
WG Partners LLP +44 (0)20 3705 9330
Nigel Barnes / Claes Spång
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFLFSAFEIEIII
(END) Dow Jones Newswires
February 06, 2020 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024